Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant

European Heart Journal

Volumn 33, Issue 9, 2012, Pages 1120-1127

  Sattianayagam, Prayman T ^a   Hahn, Angelika F ^b   Whelan, Carol J ^a   Gibbs, Simon D J ^a   Pinney, Jennifer H ^a   Stangou, Arie J ^c   Rowczenio, Dorota ^a   Pflugfelder, Peter W ^b   Fox, Zoe ^d   Lachmann, Helen J ^a   Wechalekar, Ashutosh D ^a   Hawkins, Philip N ^a   Gillmore, Julian D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Amyloid; Amyloidosis; Polyneuropathy; Transplantation; Transthyretin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PREALBUMIN; TRANSTHYRETIN ALANINE 60; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; COMPLETE HEART BLOCK; CORRELATION ANALYSIS; DEFIBRILLATOR; DIASTOLIC DYSFUNCTION; DISEASE COURSE; ECHOCARDIOGRAPHY; FAMILIAL AMYLOID POLYNEUROPATHY; FAMILY HISTORY; FOLLOW UP; GENETIC VARIABILITY; HEART AMYLOIDOSIS; HEART ATRIUM FIBRILLATION; HEART TRANSPLANTATION; HEART VALVE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QRS COMPLEX; SURVIVAL; SYSTOLIC DYSFUNCTION;

AGED; AMYLOID NEUROPATHIES, FAMILIAL; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; ELECTROCARDIOGRAPHY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; MIDDLE AGED; MUTATION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PHENOTYPE; PREALBUMIN; PROSPECTIVE STUDIES;

EID: 84860615776     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr383     Document Type: Article

References (36)

1. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75: 408-427.
2. Dwulet FE, Benson MD. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci USA 1984;81:694-698.
3. Araki S, Kurihara T, Tawara S, Kuribayashi T. Familial amyloidotic polyneuropathy in Japanese. In: Glenner GG, Pinho e Costa P, de Freitas AF, eds. Amyloid and Amyloidosis. Amsterdam-Oxford-Princeton: Excerpta Medica; 1980. p67-77.
4. Coutinho P, Martins da Silva A, Kopes Lima J, Resende Barbosa A. Forty years of experience with type 1 amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, de Freitas AF, eds. Amyloid and Amyloidosis. Amsterdam-Oxford-Princeton: Excerpta Medica; 1980. p88-98.
5. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.
6. Holmgren G, Ericzon B-G, Groth C-G, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, Pepys MB. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113-1116.
7. Rydh A, Suhr O, Hietala S-O, Åhlström KR, Pepys MB, Hawkins PN. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur J Nucl Med 1998;25: 709-713.
8. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64-71.
9. Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, O'Grady J, Pepys MB, Williams R. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation 1998;66:229-233.
10. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997;64:74-80.
11. Wallace MR, Dwulet FE, Conneally PM, Benson MD. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest 1986;78:6-12.
12. Staunton H, Dervan P, Kale R, Linke RP, Kelly P. Hereditary amyloid polyneuropathy in north west Ireland. Brain 1987;110:1231-1245.
13. Reilly MM, Staunton H, Harding AE. Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry 1995;59:45-49.
14. Kotani N, Hattori T, Yamagata S, Tokuda T, Shirasawa A, Yamaguchi S, Kobayashi S, Ikeda S. Transthyretin Thr60Ala Appalachian-type mutation in a Japanese family with familial amyloidotic polyneuropathy. Amyloid 2002;9:31-34.
15. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79: 319-328.
16. Tennent GA, Cafferty KD, Pepys MB, Hawkins PN. Congo red overlay immunohistochemistry aids classification of amyloid deposits. In: Kyle RA, Gertz MA, eds. Amyloid and Amyloidosis 1998. Pearl River, New York: Parthenon Publishing; 1999. p160-162.
17. Booth DR, Tan SY, Hawkins PN, Pepys MB, Frustaci A. A novel variant of transthyretin, 59Thr-Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation 1995;91:962-967.
18. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982;49:9-13.
19. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998;32:865-875.
20. Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, Sattianayagam PT, Gibbs SDJ, Orlandi E, Wassef NL, Bradwell AR, Hawkins PN, Gillmore JD. Outcome in renal AL amyloidosis following chemotherapy. J Clin Oncol 2011;29:674-681.
21. Benson MD, Wallace MR, Tejada E, Baumann H, Page B. Hereditary amyloidosis: description of a new American kindred with late onset cardiomyopathy. Appalachian amyloid. Arthritis Rheum 1987;30:195-200.
22. Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, Gjertsen H, Soderdahl G, Wikstrom L, Ando Y, Suhr OB, Ericzon BG. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007;7:2597-2604.
23. Conceicao I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late-and early-onset cases in Portugal. Muscle Nerve 2007;35:116-118.
24. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-1791.
25. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101-2110.
26. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78:74-82.
27. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, Liao R. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-1010.
28. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005;95:535-537.
29. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-2445.
30. Suhr OB, Anan I, Backman C, Karlsson A, Lindqvist P, Morner S, Waldenstrom A. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008;263:294-301.
31. de Cruz M, Pawarova B, Lachmann H, Gillmore J, Gibbs S, Sattianayagam P, Hawkins P, Wechalekar AD. Early detection of cardiac systolic functional impairment and correlation with NT-ProBNP change in AL amyloidosis by cardiac lateral wall tissue doppler S wave. ASH Ann Meet Abs 2009;114:2814.
32. Pomfret EA, Lewis WD, Jenkins RL, Bergethon P, Dubrey SW, Reisinger J, Falk RH, Skinner M. Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation 1998;65:918-925.
33. Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007;14: 277-282.
34. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008;40:232-239.
35. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14:3219-3230.
36. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93-97.